Braveheart Bio, Inc. priced its initial public offering at $18.00 a share, offering 21,250,000 shares of common stock, to list on the Nasdaq Global Market under the symbol BRVE. It filed a Form S-1 registration statement for an initial public offering on July 15, 2026. As of November 7, 2026, its final prospectus is on file (Form 424B4, August 6, 2026).
Who owns Braveheart Bio, Inc.?
Sell to companies like Braveheart Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Braveheart Bio, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-15. It has amended it 1 time. It filed its final prospectus on 2026-08-06, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Braveheart Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 8.2% of the class | 5%+ stakes | Source |
| September 10, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 13.5% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13D, by ORBIMED ADVISORS LLC | 17.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13D, by AH Bio Fund IV, L.P. | 11.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Frazier Life Sciences Public Fund, L.P. | 5.5% of the class | 5%+ stakes | Source |
Check before you invest in Braveheart Bio, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Braveheart Bio, Inc. and the records around it.
Braveheart Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company: Kailera Therapeutics, Inc. (Aug 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Also filing to list on the Nasdaq Global Market
IPO filings on the Nasdaq Global Market in Q3 2026, newest first.
- Syntiant Corp. (Aug 2026)
Watch Braveheart Bio, Inc.
Get an email when Braveheart Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Braveheart Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Braveheart Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Braveheart Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Market (“Nasdaq”) under the symbol “BRVE”.From the 424B4 filed 2026-08-06
Shares offered
This is the initial public offering of shares of common stock of Braveheart Bio, Inc. We are offering 21,250,000 shares of our common stock.From the 424B4 filed 2026-08-06
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2026-08-06
Use of proceeds
We currently intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, (i) to advance the development of BHB-1893 in patients with obstructive hypertrophic cardiomyopathy, including a Phase 3 clinical trial to evaluate the safety and efficacy of BHB-1893 through completion of such trial, (ii) to advance the development of BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, including a Phase 3 clinical trial to evaluate the safety and efficacy of BHB-1893 in adults with symptomatic, non-obstructive hypertrophic cardiomyopathy, through the completion of such trial, (iii) to fund research and development personnel…From the 424B4 filed 2026-08-06
Revenue
Table of Contents than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year.From the S-1 filed 2026-07-15
Net loss or income
Our net losses were $14.3 million and $66.1 million for the three months ended March 31, 2026 and for the year ended December 31, 2025, respectively.From the S-1/A filed 2026-07-30
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-15 | Registration statement filed | S-1 |
| 2026-07-30 | Registration statement amended | S-1/A |
| 2026-08-06 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Braveheart Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.